The Shanghai Stock Exchange has reprimanded a Chinese biotech company that claimed it was manufacturing a drug to treat coronavirus.
BrightGene Bio-Medical Technology Co said last month that it had received approval to mass produce remdesivir, the only drug that is thought to be effective in treating coronavirus, according to a WHO official.
But the Shanghai Stock Exchange said in a statement on Sunday that BrightGene had not received approval from China’s drug regulator to manufacture remdesivir and the company had not been licensed by the patent owner of remdesivir to make the drug.
您已閱讀66%（589字），剩余34%（297字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。